CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-30 | Pletcher Brett A EVP, Chief Legal Officer | Grant or award · Non-Qualified Stock Option (Right to Buy) | +51,039 | 51,039 | ||
| 2024-08-26 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $21.61 | $108K | 25,600 |
| 2024-08-26 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $57.26 | $286K | 20,600 |
| 2024-08-26 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 5,000 | ||
| 2024-08-20 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $56.23 | $112K | 125,004 |
| 2024-08-20 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 130,304 |
| 2024-08-20 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $56.26 | $298K | 125,004 |
| 2024-08-20 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 42,400 | ||
| 2024-08-19 | Blum Robert I President & CEO | Gift | −1,956 | 397,456 | ||
| 2024-08-12 | Blum Robert I President & CEO | Option exercise 10b5-1 | +11,500 | $6.67 | $77K | 410,912 |
| 2024-08-12 | Blum Robert I President & CEO | Sale 10b5-1 | −11,500 | $55.17 | $634K | 399,412 |
| 2024-08-12 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −11,500 | 89,727 | ||
| 2024-08-12 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $21.61 | $108K | 25,600 |
| 2024-08-12 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $55.20 | $276K | 20,600 |
| 2024-08-12 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 10,000 | ||
| 2024-08-07 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 127,004 |
| 2024-08-07 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 47,700 | ||
| 2024-08-06 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $53.74 | $107K | 121,704 |
| 2024-08-06 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $53.70 | $285K | 123,704 |
| 2024-07-30 | Blum Robert I President & CEO | Option exercise 10b5-1 | +11,500 | $6.67 | $77K | 410,912 |
Page 29 of 33 · 660 trades